Hidradenitis Suppurativa
Table of Contents
- What Hidradenitis Suppurativa Is
- Clinical Features and Hurley Staging
- Pathophysiology
- Metabolic and Systemic Associations
- Mild Treatment (Hurley Stage I)
- Moderate Treatment (Hurley Stage II)
- Severe Treatment (Hurley Stage III)
- Quality of Life and Mental Health
- Key Research Papers
- Connections
- Featured Videos
What Hidradenitis Suppurativa Is
Hidradenitis suppurativa (HS) — also called acne inversa — is a chronic, painful inflammatory skin disease affecting the hair follicles in areas rich in apocrine glands: the armpits, groin, perianal area, buttocks, and under the breasts. Despite its name suggesting sweat gland involvement, HS is now understood to originate in the hair follicle, not the apocrine gland itself — the glands are involved secondarily.
HS is severely underdiagnosed, with an average diagnostic delay of 7–10 years. Many patients are told they have "boils" or "infected ingrown hairs" and cycle through general practitioners, surgeons, and emergency rooms before reaching a dermatologist who recognizes the condition. Estimates of how common it is range from about 0.1% of people (US studies of routine health records) to 1% or more (European studies, which also count people who were never diagnosed) — a more than tenfold gap that a 2020 review calls a high priority to resolve. In North American and European patients it is about three times more common in women than men, while in South Korean patients the ratio is reversed (about one woman for every two men). Onset typically occurs after puberty, usually in the teens to mid-30s.
HS has one of the highest rates of pain, depression, and quality-of-life impairment of any dermatological condition. The combination of chronic pain, scarring, drainage, and odor significantly impacts relationships, employment, and daily functioning.
Clinical Features and Hurley Staging
HS presents as recurrent, painful nodules and abscesses in characteristic locations. Unlike a typical abscess caused by a bacterial infection, HS abscesses are sterile initially — bacteria colonize secondarily. Key features:
- Painful nodules and abscesses: Tender, warm, red lumps under the skin, typically 1–3 cm. May spontaneously rupture and drain malodorous fluid, or coalesce and persist for weeks.
- Sinus tracts: Tunnels that form under the skin connecting multiple nodules. These are a hallmark of more advanced disease and rarely heal without intervention.
- Scarring: Rope-like hypertrophic scars (cord-like bands of scar tissue) form from repeated cycles of inflammation and healing.
- Characteristic locations: Axillae (armpits), groin and inner thighs, perianal/perineal area, buttocks, inframammary folds.
Hurley Staging (most widely used staging system):
- Hurley Stage I: One or more isolated abscesses without sinus tracts or significant scarring. Lesions appear, resolve, and recur. No interconnection between lesions.
- Hurley Stage II: Recurrent abscesses with one or more sinus tracts and scarring. Multiple separated lesions, but still involving distinct areas.
- Hurley Stage III: Diffuse involvement of an entire area. Multiple sinus tracts. No normal skin remains in affected regions. Continuous weeping and odor.
Pathophysiology
The central event in HS is follicular occlusion — the opening (infundibulum) of the hair follicle becomes blocked, causing the follicle to dilate and eventually rupture. The rupture releases keratin, bacteria, and follicular contents into the surrounding dermis, triggering an intense inflammatory response.
This process is NOT a primary infection. Bacterial cultures of early HS lesions are often sterile or show only skin commensal bacteria. Antibiotics help not by eradicating infection but by reducing inflammatory bacterial signals (particularly from Staphylococcus epidermidis and Cutibacterium acnes). This distinction matters — HS does not respond to antibiotic courses the way a typical infection does, and treating it as simple cellulitis or a boil leads to inappropriate management.
Key pathophysiological elements:
- Dysregulation of the interleukin-17 (IL-17), interleukin-1 (IL-1), and tumor necrosis factor-alpha inflammatory pathways (same pathways implicated in Crohn's disease and psoriasis)
- Altered adipokine signaling — adiponectin and leptin dysregulation links HS to obesity
- Defects in Notch signaling (a genetic component — NCSTN, PSENEN mutations in familial HS)
- Androgen receptor signaling amplifies sebaceous activity, explaining female predominance and post-pubertal onset
Metabolic and Systemic Associations
HS is increasingly recognized as a systemic inflammatory disease, not just a skin condition:
- Obesity: 58–90% of HS patients are overweight or obese. Even modest weight loss (10% body weight) significantly reduces HS severity — mechanical friction in skin folds and adipose-tissue-derived inflammatory signals both contribute.
- Metabolic syndrome: Elevated rates of hypertension, dyslipidemia, and insulin resistance. HS patients have roughly double the risk of type 2 diabetes.
- Polycystic Ovary Syndrome (PCOS): Occurs in approximately 20–30% of women with HS. The androgen excess in polycystic ovary syndrome likely worsens follicular pathology.
- Inflammatory bowel disease (Crohn's disease): 1.5–3% of HS patients also have Crohn's disease. Both conditions involve tumor necrosis factor-alpha-driven inflammation and respond to anti-TNF biologics. Perianal HS and perianal Crohn's can be very difficult to distinguish clinically.
- Depression and anxiety: Extremely common — HS has one of the highest psychiatric comorbidity rates of any skin disease. Chronic pain, disfigurement, and social isolation drive mental health burden. Depression screening with validated questionnaires is described as part of HS care.
- Squamous cell carcinoma (SCC): A rare but serious complication. Chronic longstanding HS in the perianal, perineal, or groin region can develop into SCC — the chronic inflammation and scarring creates a cancer-prone microenvironment. A wound in long-standing HS that does not heal can be squamous cell carcinoma, which is diagnosed by biopsy (a small tissue sample).
Mild Treatment (Hurley Stage I)
For mild disease with isolated nodules and abscesses:
- Topical clindamycin 1%: Applied twice daily to affected areas. Reduces surface bacteria and has mild anti-inflammatory effects. Less effective for deep nodules but useful for superficial inflammation and maintenance.
- Benzoyl peroxide wash (5–10%): Used as a wash in the shower to reduce bacterial colonization. Can be drying; some people alternate it with a gentle cleanser.
- Chlorhexidine gluconate wash (4%): Antimicrobial skin wash for affected areas. Reduces bacterial burden and may decrease flare frequency.
- Weight loss: For patients who are overweight, even 10% body weight reduction significantly reduces HS disease severity and flare frequency. Approaches described include diet, activity and other lifestyle programmes.
- Smoking cessation: A major modifiable risk factor for HS. Smokers have significantly more severe disease. Nicotine promotes follicular hyperkeratosis and inflammation. Cessation alone can reduce severity substantially.
- Intralesional triamcinolone: An injection of diluted corticosteroid directly into an acute inflamed nodule or abscess. Provides rapid reduction in pain and inflammation for an individual lesion within 24–48 hours. Not a long-term treatment but extremely useful for acute flares.
Moderate Treatment (Hurley Stage II)
For recurrent disease with sinus tract formation:
- Oral tetracyclines (doxycycline, minocycline): The most commonly prescribed systemic treatment. Used at anti-inflammatory (not antibiotic) doses — doxycycline 100 mg twice daily for 3+ months. Reduces flare frequency but rarely produces complete remission. Side effects: photosensitivity (doxycycline), blue-black skin discoloration (minocycline with long-term use).
- Clindamycin + rifampin combination: More effective than clindamycin alone. Clindamycin 300 mg + rifampin 300 mg, both twice daily (rifampin 600 mg a day in total), for 10 weeks. In a French series of 116 consecutive patients on this combination, the median Sartorius severity score fell from 29 to 14.5 after 10 weeks; 8 patients (6.9%) stopped because of side effects. Rifampin speeds up the liver's breakdown of many other drugs (it induces liver enzymes); hormonal contraceptives become less reliable while it is taken.
- Oral zinc gluconate: Anti-inflammatory and anti-androgenic properties. 90 mg/day in divided doses. A 2007 open pilot study of 22 people (mostly Hurley stage I or II) given 90 mg zinc gluconate a day reported 8 complete and 14 partial remissions; 4 had side effects, mainly stomach upset. There was no placebo group, so how much of the improvement came from the zinc itself is not known. Well-tolerated, inexpensive. Takes 3–4 months to see full effect.
- Spironolactone (for women): An anti-androgen medication with diuretic properties. 50–150 mg daily. Addresses the hormonal component in women, particularly those with concurrent polycystic ovary syndrome. Reduces sebum production and androgen receptor signaling.
- Dapsone: An anti-inflammatory sulfonamide used in some cases. It can cause hemolytic anemia (breakdown of red blood cells) in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, which a blood test detects before treatment starts.
Severe Treatment (Hurley Stage III)
For advanced disease with diffuse involvement:
- Adalimumab: The first U.S. Food and Drug Administration-approved biologic for HS (approved 2015). A tumor necrosis factor-alpha inhibitor. Label dosing for adults: 160 mg on day 1, 80 mg on day 15, then from day 29 either 40 mg every week or 80 mg every other week. In the pivotal PIONEER I & II trials, about 42% and 59% of patients on weekly adalimumab achieved HiSCR (Hidradenitis Suppurativa Clinical Response — ≥50% reduction in abscess and inflammatory nodule count) at week 12, versus 26% and 28% on placebo. Requires TB screening and vaccination review before starting. Long-term data show sustained benefit.
- Secukinumab: An interleukin-17A (IL-17A) inhibitor approved for HS in 2023. In two identical trials (SUNSHINE and SUNRISE, 1,084 adults analysed), secukinumab every 2 weeks gave a clinical response at week 16 in 45% and 42% of people, versus 34% and 31% on placebo; every-4-week dosing reached 42% (not significantly different from placebo) and 46%. Responses lasted to week 52. An alternative for patients who do not respond to or tolerate adalimumab. Monthly subcutaneous injections after loading dose.
- Bimekizumab: Blocks two forms of interleukin-17 (A and F). The U.S. Food and Drug Administration label now lists adults with moderate to severe HS (approved for HS in November 2024). In the BE HEARD I and II trials (1,014 adults), 48% and 52% of people given bimekizumab every 2 weeks reached HiSCR50 at week 16, versus 29% and 32% on placebo, and responses were maintained or increased to week 48.
- Wide surgical excision: The only true cure for advanced HS. The affected region of skin (axilla, groin, etc.) is surgically removed with wide margins down to the fascia, ensuring all sinus tracts are removed. Heals by secondary intention (open wound) or skin grafting. Recurrence rate after truly wide excision is low (~20%). Not suitable for all patients due to extent of surgery required.
- CO2 laser ablation (deroofing): A less radical surgical option — the laser vaporizes the roof of sinus tracts and nodules, exposing the floor and allowing healing. Good results for localized disease. Can be performed under local anesthesia.
- Pain management: Chronic pain is a major burden. Multimodal approaches including nonsteroidal anti-inflammatory drugs (NSAIDs), gabapentinoids (pregabalin), and psychological support are important components of care.
Quality of Life and Mental Health
HS consistently ranks among the skin diseases with the greatest impact on quality of life — comparable to or worse than psoriasis, eczema, and many other chronic skin conditions. This is not surprising given the combination of:
- Chronic, unpredictable pain (often rated 7–9/10 during flares)
- Malodorous drainage that is difficult to conceal
- Scarring in intimate and visible areas
- Restriction of physical activity and movement
- Impact on intimate relationships, sexual function, and self-image
- Stigma from a poorly understood condition that is sometimes misattributed to poor hygiene
Rates of depression (up to 43%) and anxiety are significantly elevated in HS patients. Suicide ideation rates are also higher than in the general population, and a 2020 review of HS epidemiology reports that completed suicide rates in people with HS are more than double those in people without it. Mental health screening and referral are described as a routine part of HS care. Patient support organizations (HS Foundation, HS Warriors) offer community and educational resources.
Important patient education points: HS is not caused by poor hygiene, it is not contagious, and it is not your fault. It is a complex genetic-immune disease that requires comprehensive management, not just better washing habits.
Key Research Papers
Key peer-reviewed studies on hidradenitis suppurativa. Each PMID link opens the study on PubMed.
- Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. — PubMed PMID: 22236226
- Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23(9):985-998. — PubMed PMID: 19682181
- Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546-1549. — PubMed PMID: 26198191
- Gulliver W, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343-351. — PubMed PMID: 26831295
- Schlapbach C, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790-798. — PubMed PMID: 21641076
- Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990-998. — PubMed PMID: 32880911
- Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148-154. — PubMed PMID: 19590173
- Zouboulis CC, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization — systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19-31. — PubMed PMID: 30176066
- Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539-561. — PubMed PMID: 19293006
- Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434. — PubMed PMID: 27518661
- Brocard A, Knol AC, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology. 2007;214(4):325-327. — PubMed PMID: 17460404
- Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. — PubMed PMID: 36746171
- Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504-2519. — PubMed PMID: 38795716
Curated PubMed topic searches: